Targeting FGFR mutations offers new hope for bone repair in skeletal disorders

Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect craniofacial and mandibular development.

5 Trends to Watch for Outpatient Therapists in 2025

What You Should Know: – Today, StrataPT, the only billing-aware practice management platform for outpatient therapy clinics, is helping practitioners grow and scale next year by sharing

December 4, 2024

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026 – Biotech Investments

Takeda Pharmaceutical Company Limited / Key word(s): Personnel Takeda Pharmaceutical Company Limited: Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

January 31, 2025

Pfizer lands FDA approval for $6.7B ulcerative colitis drug, taking on antibodies as an oral alternative

Pfizer has secured an FDA approval for etrasimod in moderate to severe ulcerative colitis. It’s the second sphingosine-1-phosphate (S1P) drug to arrive on the UC

October 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.